Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors
Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors
复制标题
DOI：
10.1111/j.1600-0609.2005.00514.x
复制
发表时间：
2005-10-01
影响因子：
3.1
通讯作者：
Shin, IH
中科院分区：
文献类型：
--
作者：
Kim, DH;Sohn, SK;Shin, IH
背景：关于CD56 +自然杀伤（NK）细胞剂量对同种异体外周血干细胞移植（PBSCT）结果的作用知之甚少。最近，高剂量的NK细胞与较低的严重移植物抗宿主病（GVHD）发生率相关。目前的研究试图评估NK细胞剂量对同种异体PBSCT移植结果的影响。方法和材料：对61例细胞因子动员的PBSC受者进行分析，根据CD34+细胞和NK细胞输注剂量与总生存率（OS）、非复发死亡率（NRM）、GVHD和感染事件的关系。结果：高剂量NK细胞组（>= 5 × 10(7) /kg） NRM发生率（P = 0.0186）和感染事件发生率（P = 0.0107）较低。在多变量分析中，高剂量NK细胞与CD34+细胞剂量的NRM (P = 0.042) （P = 0.018）和CD34+细胞剂量的感染事件（P = 0.013） （P = 0.016）相关。高NK细胞输注组在+ 90、+ 180和+ 365天的连续测量中也显示出更快的免疫恢复。结论：高剂量NK细胞可能与CD34 +细胞一起减少NRM和感染事件，在改善移植预后方面发挥重要作用。
Background: Little is known about the role of the CD56 + natural killer (NK) cell dose on the outcome of allogeneic peripheral blood stem cell transplantation (PBSCT). Recently, higher dose of NK cells has been associated with a lower incidence of severe graft-versus-host disease (GVHD). The current study attempted to evaluate the effect of the NK cell dose on transplant outcomes in allogeneic PBSCT setting. Methods and materials: Sixty-one cytokine mobilized PBSC recipients were analyzed according to the infused dose of CD34+ cells and NK cells in relation to overall survival (OS), non-relapse mortality (NRM), GVHD, and infectious events. Results: The group received a higher dose of NK cells (>= 5 x 10(7) /kg) showed a lower incidence of NRM (P = 0.0186) and infectious events (P = 0.0107). In a multivariate analysis, a higher dose of NK cells was correlated to better transplant outcomes for NRM (P = 0.042) with CD34 + cell dose (P = 0.018), and for infectious events (P = 0.013) with CD34+ cell dose (P = 0.016). Higher NK cell infusion group also showed a faster immune recovery in serial measurements at days + 90, + 180, and + 365. Conclusions: High dose of NK cells may play an important role in improving transplant outcomes, in terms of reducing NRM and infectious events together with CD34 + cells.